CliffBio
small molecule

DESVENLAFAXINE SUCCINATE

DESVENLAFAXINE SUCCINATE

Loss of exclusivity—loss of exclusivity
CompanyLupin →See this company's full patent-cliff portfolio

Drug detail

Brand nameDESVENLAFAXINE SUCCINATE
Active ingredientDESVENLAFAXINE SUCCINATE
StrengthEQ 50MG BASE
Dosage formTABLET, EXTENDED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalJune 2015
Marketing statusRX

More from Lupin

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.